4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine | CAS:16372-08-0

We serve 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine CAS:16372-08-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

Chemical Name:4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine
CAS.NO:16372-08-0
Synonyms:4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine
4-Chlor-7H-pyrrolo[2,3-d]pyrimidin
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 311.9ºC at 760 mmHg
Molecular Formula C6H4ClN3
Molecular Weight 153.569
Index of Refraction 1.720
 
Specification:
Appearance:Off-white powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ruxolitinib(CAS:941678-49-5).



Contact us for information like 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Chlor-7H-pyrrolo[2,3-d]pyrimidin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine Use and application,4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine technical grade,usp/ep/jp grade.


Related News: Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.4-hydroxy-2,5-dimethylfuran-3-one manufacturer On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday.4-Chloro-3-fluoroaniline supplier On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday.2-Bromo-3-fluorotoluene vendor Though many of the remedies have been in use for hundreds of years, critics argue that there is no verifiable scientific evidence to support their supposed benefits.Therefore, the growth of the global pharmaceutical market has greatly affected the development of the entire intermediate and API industry.